Berberine attenuates A-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer's disease
Novo Nordisk to cut GLP-1 prices in tough US market Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US, promising to slash the monthly cost of its semaglutide-based Wegovy weight-loss therapy and Ozempic for type 2 diabetes
A result that does not fit the clinical picture should not be assumed to reflect true hypercobalaminemia, but it should not be assumed to be macro-B12 either
Transparent practices: Suppliers who clearly communicate their sourcing, testing, and handling practices demonstrate commitment to quality
We also have NEW lower pricing on brand-name Zepbound and Wegovy
Functional medicine providers adopt a holistic perspective, considering genetic, environmental, and lifestyle factors to identify the underlying causes of illness